Patients do as well on generic antiplatelet drugs as more expensive brand-name product

March 13, 2018, American Heart Association

Generic anti-platelet drugs seem to work as well as a brand name drug for heart patients, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

When a Canadian health system switched from prescribing the brand-name anti-platelet drug Plavix to a far-cheaper generic version, and chest pain were no more likely to die from any cause or be re-hospitalized for a attack or unstable angina within a year than those prescribed Plavix (17.9 percent vs. 17.6 percent).

In addition, there were no significant differences between the drug groups in the percent of patients who died or were hospitalized for any reason; had a stroke or ; or who developed bleeding as a side effect of treatment.

"People can safely use generic clopidogrel. This large and real-world study should be reassuring to physicians and healthcare organizations who have been concerned about changing what is prescribed," said Dennis T. Ko, M.D., M.Sc., lead study author and senior scientist at the Institute for Clinical Evaluative Sciences (ICES) in Toronto.

In Canada and the United States, generic drugs are approved based on small studies in healthy people showing that the active ingredient is released at equivalent levels and over the same timeframe. That suggests, but doesn't prove, that the generic product will also have the same safety and medical benefit.

Clopidogrel is used to treat patients with , , stroke or peripheral vascular disease.

Researchers compared outcomes in patients (average age 77, 57 percent male) who were prescribed clopidogrel after hospitalization for a heart attack or heart-related chest pain (unstable angina) in Ontario, Canada, where the Ministry of Health began to automatically substitute generic clopidogrel for Plavix once the brand name drug's patent expired in 2012. Between 2009 and 2014, 12,643 patients were prescribed Plavix and 11,887 generic clopidogrel.

Plavix cost about $2.58 Canadian dollars per pill in 2010 and was projected to cost the Ontario Drug Benefit Program $72.8 million by 2012. But by switching to a generic, which costs $0.39 per pill in 2018, the expense was only $19 million Canadian dollars.

"Plavix was one of the most commonly used drugs in cardiology, so switching to generics can reduce a lot of cost for individuals and health systems," said Ko, who is also a cardiologist at the Schulich Heart Centre of the Sunnybrook Health Sciences Centre at the University of Toronto.

While the study was conducted in Canada, the results should apply to the United States, even if the generic offerings are slightly different, according to the researchers.

"There are quite a few different generic brands. In this study, we considered them as a group, but later found no differences in outcome when we compared between different generics," said co-principal investigator Cynthia Jackevicius, Pharm.D., M.Sc., professor of pharmacy at Western University of Health Sciences and senior adjunct scientist at ICES.

The American Heart Association recommends clopidogrel—sometimes in combination with other drugs—for patients who have had acute coronary syndrome ( or heart attack) or stroke.

Explore further: Plavix's new generic status could be boon for patients

More information: Circulation: Cardiovascular Quality and Outcomes (2018). DOI: 10.1161/CIRCOUTCOMES.117.004194

Related Stories

Plavix's new generic status could be boon for patients

May 15, 2012
(HealthDay) -- The blockbuster drug Plavix (clopidogrel), used to prevent clotting in some heart patients, will go off patent in the United States on Thursday, making it considerably more affordable.

Generic versions of plavix approved

May 18, 2012
(HealthDay) -- The first generic versions of Plavix (clopidogrel bisulfate) have been approved by the U.S. Food and Drug Administration.

Personalized approach to selecting antiplatelet drugs improves outcomes

March 12, 2018
Patients with acute coronary syndrome experienced a substantially lower rate of heart attack, stroke, death from cardiovascular causes and major bleeding at 12 months if genetic information was used to inform the selection ...

Adverse events spike after blood pressure meds go generic in Canada

October 3, 2017
One month after generic versions of three widely-used blood pressure drugs became available in Canada, hospital visits for adverse events spiked in generic drug users, according to new research in Circulation: Cardiovascular ...

More potent anti-clotting drugs with angiography may benefit patients with acute chest pain

August 15, 2013
Current methods to treat acute coronary syndrome conditions, such as heart attack, include artery-clearing procedures (e.g., percutaneous coronary intervention or coronary artery bypass grafting) with medications, or medications ...

Recommended for you

Drinking alcohol makes your heart race

March 18, 2018
The more alcohol you drink, the higher your heart rate gets, according to research presented today at EHRA 2018 Congress, organized by the European Society of Cardiology.

Study of nearly 300,000 people challenges the 'obesity paradox'

March 15, 2018
The idea that it might be possible to be overweight or obese but not at increased risk of heart disease, otherwise known as the "obesity paradox", has been challenged by a study of nearly 300,000 people published in in the ...

Mending broken hearts with cardiomyocyte molds

March 13, 2018
2.5 billion. That's approximately the number of times the human heart beats in 70 years. And sometimes during the course of its unrelenting contractions and relaxations, the heart muscle can no longer bear the strain.

Common infections a bigger heart disease and stroke risk than obesity

March 13, 2018
A major study into the impact of common infections leading to hospitalisation has found they may substantially increase the risk of heart attacks, strokes and in the longer term, death.

Aspirin prevents venous thromboembolism following major orthopedic surgeries, study finds

March 13, 2018
A multicentre, double-blind, randomized, controlled clinical trial of patients who underwent total hip or knee replacement surgery showed that aspirin was as effective as rivaroxaban, the standard anti-coagulation medication, ...

Barbershop-based healthcare study successfully lowers high blood pressure in African-American men

March 12, 2018
African-American men successfully lowered their high blood pressure to healthy levels when aided by a pharmacist and their local barber, according to a new study from the Smidt Heart Institute.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.